Sharemaestro Newsreel

Aquestive Prepares FDA Resubmission for Severe Allergy Treatment Following Successful Study

Aquestive Therapeutics (AQST) announced positive results from human factors and pharmacokinetic validation studies for its Anaphylm sublingual film, a severe allergy treatment. These studies address prior FDA feedback, demonstrating significant improvements in product usability and effective drug delivery even with slight misplacement. The company …

Is Neurocrine Biosciences (NBIX) Fully Valued As It Enters Phase 1 Obesity Testing?

Neurocrine Biosciences (NBIX) has commenced a Phase 1 study for its obesity treatment candidate, NBIP 1968, following positive Q2 and H1 2026 financial results. Despite recent stock momentum and a current share price of $163.41, Simply Wall St's analysis suggests the company might be …

Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Gap Down - Time to Sell?

QDEL Q2 Earnings & Revenues Beat Estimates, 2026 Guidance Lowered

QuidelOrtho Corporation QDEL delivered adjusted earnings per share (EPS) of 13 cents in second-quarter 2026, up 8.3% year over year. The figure beat the Zacks Consensus Estimate by 425%. The adjustments include expenses related to the amortization of intangibles, acquisition and integration costs, among …

Integer Holdings Q2 Earnings & Revenues Top Estimates, Margins Decline

Integer Holdings Corporation ITGR delivered adjusted earnings per share (EPS) of $1.60 in the second quarter of 2026, up 3.2% year over year. The figure beat the Zacks Consensus Estimate by 15.9%. The adjustments include expenses related to the amortization of intangible assets and …

Cronos Group Inc. stock falls Monday, underperforms market

Cronos Group Inc. (CRON) stock decreased by 3.23% to $3.00 on Monday, underperforming the broader market. This drop ended a two-day winning streak for the company's shares. The NASDAQ Composite Index also fell 0.32%, and the Dow Jones Industrial Average fell 0.11%.

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cut

ANI Pharmaceuticals ANIP reported second-quarter 2026 adjusted EPS of $2.21, beating the Zacks Consensus Estimate of $2.01. The reported figure rose 23% year over year, driven by higher sales during the quarter. Quarterly revenues totaled $266 million, up 26% from the year-ago period. The …

Tilray Brands to cease production at US brewery Terrapin

Tilray Brands will cease brewing operations at its Terrapin Beer Co. facility in Athens, Georgia, by September 25, 2026, as part of a cost-cutting initiative called 'Project 420'. The taproom and other operations at the site will remain open, and Terrapin will continue as …

Dr. Reddy’s (RDY) to end Novartis India brand deal after Sept. 2026

Dr. Reddy's Laboratories Limited announced the termination of its distribution and promotion agreement with Novartis India Limited, effective September 30, 2026. This decision follows a change in the controlling shareholding of Novartis India. Dr. Reddy's will continue to commercialize the covered brands until the …

Aquestive Therapeutics (NASDAQ:AQST) Shares Gap Up - Should You Buy?

Optimi Health Corp (CN:OPTI) Shares Under Pressure as Psychedelic Market Uncertainty and Development Risks Weigh on Sentiment

Optimi Health Corp (CN:OPTI) shares recently declined by 2.40% due to investor caution surrounding the psychedelic medicine market, regulatory uncertainties, and broader biotechnology sector volatility. The company, which manufactures and distributes pharmaceutical-grade psychedelic products like psilocybin, faces challenges in market adoption, funding, and competition. …

Evotec (NASDAQ:EVO) Shares Gap Up - Here's What Happened

Evotec (NASDAQ:EVO) shares gapped up before the market opened, opening at $2.10 after closing at $2.00, and last traded at $2.0950 on modest volume. Analyst sentiment for the Germany-based biotechnology company is mixed, with a consensus "Hold" rating and a $3.00 average price target, …

PRGO vs. NEOG: Which Stock Is the Better Value Option?

Investors with an interest in Medical - Products stocks have likely encountered both Perrigo (PRGO) and Neogen (NEOG). But which of these two companies is the best option for those looking for undervalued stocks? Let's take a closer look. Everyone has their own methods …

OTLK Up More Than 300% in 3 Months: Here's What You Should Know

Shares of Outlook Therapeutics OTLK have witnessed a significant surge over the past three months, primarily driven by growing investor optimism related to the company's sole product, Lytenava, which is approved for the treatment of patients with wet age-related macular degeneration (wet AMD). OTLK's …

Key Earnings Reports Ahead

Last week was "Jobs Week," and the week before held the most recent Fed meeting on interest rates, along with several marquee names reporting quarterly earnings. This week, we pivot to "Inflation Week," with Wednesday and Thursday morning bringing new monthly price index data. …

Asian Equities Traded in the US as American Depositary Receipts Decline in Monday Trading

Asian equities traded in the US as American depositary receipts opened the week slightly lower Monday morning, declining 0.14% to 3,019.02 on the S&P Asia 50 ADR Index.From North Asia, the gainers were led by brand platform 36Kr (KRKR) and video display maker LG …

Trading Week Awaits Inflation Reports Starting Wednesday

Monday, August 10th, 2026 Last week was "Jobs Week," and the week before held the most recent Fed meeting on interest rates, along with several marquee names reporting quarterly earnings. This week, we pivot to "Inflation Week," with Wednesday and Thursday morning bringing new …

Here's Why Replimune Stock Skyrockets Nearly 223% in 3 Months

Shares of Replimune Group REPL have surged nearly 223% over the past three months, as the company steadily advanced its lead oncolytic immunotherapy, RP1 (vusolimogene oderparepvec), toward regulatory approval and strengthened the broader pipeline. The rally has been driven primarily by a series of …

Kiniksa Pharmaceuticals International, plc Class A Actuals & Estimates (NASDAQ:KNSA)

This article provides an overview of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) stock performance, financial actuals, and analyst estimates. It includes current stock price, historical highs and lows, volatility, market capitalization, and details on recent and upcoming earnings reports, revenue, and net income. The article …

Stocks in play: Aurora Cannabis Inc.

Aurora Cannabis Inc. announced the voting results from its Annual General Meeting of Shareholders, held virtually on August 7. The company's shares were trading down at $4.09. The article also briefly mentions other investment-related topics such as gold prices and quantum computing.

Kamada Ltd. expected to post earnings of 11 cents a share - Earnings Preview

Kamada Ltd. is projected to report earnings of 11 cents per share, according to an earnings preview. This information is provided through TradingView News, which sources content from Reuters. The full article is available to subscribers of TradingView's news services.

Evotec and Odyssey Therapeutics team up to accelerate AI-driven drug discovery for autoimmune diseases

Evotec SE and Odyssey Therapeutics have formed a strategic R&D collaboration to accelerate AI-driven drug discovery for autoimmune and inflammatory diseases. The partnership will combine Evotec’s data-driven drug discovery platform, AI-enabled technologies, and screening capabilities with Odyssey’s expertise in disease biology to identify and …

Tilray Brands Expects to Hit a Major Milestone for the Current Fiscal Year: $1 Billion in Annual Revenue. Here's How it Plans to Get There

Tilray Brands (NASDAQ: TLRY) recently posted record earnings numbers and is focused on even more growth ahead. For the coming fiscal year, it anticipates full-year revenue will exceed $1 billion. It would be a huge milestone for the company, whose growth prospects have been …

Takeda CSO Chris Arendt on Transforming Drug Discovery & the R&D Pipeline

Takeda is entering one of the most pivotal moments in its 245-year history, with a late-stage pipeline poised to transform patient outcomes across three therapeutic areas. Chief Scientific Officer Chris Arendt goes Inside the ICE House to discuss the science behind drug candidates targeting …

5 Stocks With Recent Price Strength to Tap August Rally

U.S. stock markets returned to a northward journey after a mixed June and July. In the first week of August, the Dow, the S&P 500 and the Nasdaq Composite rallied 3%, 3.6% and 5.2%, respectively. All three major stock indexes posted their best weekly …

Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash

Theravance Biopharma reported its Q2 2026 financial results, including $20.7 million in revenue from its Viatris collaboration and a GAAP net loss of $5.9 million, with $387.7 million in cash and marketable securities. The company highlighted strong YUPELRI performance, a pending acquisition by Zymeworks, …

Harrow earnings up next: Can ophthalmic firm stage Q2 comeback?

Harrow Health Inc. is set to report its second-quarter earnings, with analysts expecting a significant rebound in revenue and a narrowed loss after a disappointing first quarter. Despite unanimous "buy" ratings from analysts and a substantial implied upside, investors are keenly watching if the …

Earnings To Watch: Aquestive Therapeutics Inc (AQST) Q2 2026 -- GF Value Sees 35% Downside

Aquestive Therapeutics Inc (AQST) is preparing to release its Q2 2026 earnings on August 11, 2026, with revenue expected at $11.42 million and earnings at $-0.12 per share. While analysts predict a significant upside of 125.61% based on average price targets, GuruFocus's GF Value …

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm Sublingual Film

Aquestive Therapeutics has announced positive topline results from its human factors and pharmacokinetic studies for Anaphylm™ (dibutepinephrine) sublingual film. These results support the planned resubmission of its New Drug Application (NDA) to the FDA in Q3 2026, addressing previous issues with packaging and administration. …

Canaccord Genuity Group Cuts ANI Pharmaceuticals (NASDAQ:ANIP) Price Target to $90.00

Canaccord Genuity Group has lowered its price target for ANI Pharmaceuticals (NASDAQ:ANIP) to $90.00 from $91.00, while maintaining a "hold" rating. This implies a potential upside of 15% from the previous closing price. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of …

Zoetis (ZTS) Looked Like a Winner. What Went Wrong?

Brown Advisory, an investment management company, released its "Brown Advisory Global Leaders Strategy" for the second quarter of 2026 investor letter. A copy of the letter can be downloaded here. Brown Advisory's Global Leaders Strategy delivered a net return of 4.6% in the second …

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector …

1 Healthcare Stock Worth Your Attention and 2 We Ignore

1 Healthcare Stock Worth Your Attention and 2 We Ignore From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Shareholders who bet on the industry have been rewarded lately as healthcare stocks have returned 18.3% over …

Alvotech to Report Financial Results for H1 2026

Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company, announced it will release its financial results for the first half of 2026 on Wednesday, August 19, 2026, after the U.S. market close. The company will also host a webcast with a live Q&A on Thursday, …

BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI)

Aquestive Therapeutics releases Anaphylm human factors, clinical study presentation materials

Aquestive Therapeutics has released supplemental materials on human factors and clinical results for its Anaphylm (dibutepinephrine) sublingual film program. A resubmission human factors study showed fewer use issues compared to the original NDA study, with a median open time reduced to 3 seconds. A …